Gout is a disease that is caused by frequent attacks of acute inflammatory arthritis. The symptoms of this disease include red and swollen joint, itching skin, limited movement of the affected part, and others. Also, the uric acid crystallizes and the crystals deposit in joints, tendons and adjacent tissues which cause a gout attack. The human body produces uric acid when it is broken down into purines. Purines are substances that are already present naturally in the body in the form of food consumed by the humans. It is caused due to a combination of genetic factor and diet. Usually, the person consuming large amounts of meat and beer faces this disease.
The global gout disease treatment market is segmented on the basis of disease therapeutics and the conditional stage. The conditional stage segment is sub-segmented as acute gout and chronic gout. The therapeutic segment is further sub-segmented as urate-lowering therapies and inflammatory. The global market is segmented on the basis of the product as colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), and corticosteroids. NSAIDs are widely used for the treatment of gout disease, while corticosteroids and colchicines are the alternative treatment for the patients who are unable to tolerate the effects of NSAIDs.
The increase in the number of gout disease incidences and strong development of the treatment are some of the major factors driving the global gout disease treatment market. Improvised study on gout therapeutics and introduction of niche drugs are other factors boosting the growth of the global gout disease treatment market. Progressive collaboration between major companies and quick product launches are some key factors impacting the growth of the market in a positive way. On the other hand, strict regulations and patent expiry of various drugs may act key restraining factors for the global gout disease treatment market.
North America and Europe dominate the global gout disease treatment market mainly owing to the enhanced pharmaceutical research in this area. North America is the leading player in the gout therapeutics market due to increased geriatric population with modernized routine disorders. In addition, the U.S holds the biggest market for gout disease treatment, followed by Canada in North America. Furthermore, Asia is anticipated to witness high growth in the near future owing to increasing awareness among people about the disease. Japan, China, and India are expected to grow rapidly in the gout disease treatment market in Asia.
Some of the major players dominating the global gout disease treatment market are Novartis AG, AstraZeneca PLC, Polaris Group, Teijin Pharma Limited, BioCryst Pharmaceuticals, Inc., Nippon Chemiphar Co., Ltd., and JW Pharmaceutical Corporation. Other key players influencing the global market are Addex Therapeutics, Takeda Pharmaceutical Company, LG Life Sciences Ltd., Pfizer, and Merck.
Gout Disease Treatment Market: Regional Segment Analysis
- North America
- Asia Pacific
- Latin America
- Middle East and Africa